NRx Pharmaceuticals (NASDAQ:NRXP) Lifted to Strong-Buy at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals (NASDAQ:NRXP) to a strong-buy rating in a report released on Monday, Zacks.com reports.

A number of other brokerages have also recently commented on NRXP. HC Wainwright lifted their price objective on NRx Pharmaceuticals from $2.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Ascendiant Capital Markets boosted their target price on NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a research note on Thursday, September 12th.

NRx Pharmaceuticals Stock Up 0.8 %

Shares of NRx Pharmaceuticals stock opened at $1.21 on Monday. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $7.33. The business has a fifty day simple moving average of $1.64 and a 200 day simple moving average of $2.54. The stock has a market cap of $12.95 million, a PE ratio of -0.38 and a beta of 1.25.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.06. Analysts expect that NRx Pharmaceuticals will post -3.25 EPS for the current fiscal year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.